This study employs a basket design to concurrently investigate DKN-01 as monotherapy and in combination with paclitaxel in patients with recurrent epithelial endometrial cancer (EEC), epithelial ovarian cancer (EOC), or carcinosarcoma (malignant mixed Mullerian tumor [MMMT]. Thus, 6 distinct patient groups are being independently investigated:~300mg DKN-01 monotherapy in recurrent EEC (Group 1)~300mg DKN-01+paclitaxel in recurrent EEC (Group 2)~300mg DKN-01 monotherapy in recurrent EOC (Group 3)~300mg DKN-01+paclitaxel in recurrent EOC (Group 4)~600mg DKN-01 monotherapy in recurrent carcinosarcoma (MMMT) (Group 5)~600mg DKN-01+paclitaxel in recurrent carcinosarcoma (MMMT) (Group 6)
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma